Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
ASH Annual Meeting 2021 Conference Coverage
Advertisement
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Damon E. Houghton, MD, MS, of Mayo Clinic in Rochester, Minnesota, presented the data at the ASH Annual Meeting 2021.
This lack of benefit was seen in the entire study population.
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.